Linda Rehfeld1, Eugenia Funk2, Shalinee Jha3, Peter Macheroux3, Olle Melander4, Andreas Bergmann2. 1. Sphingotec Therapeutics GmbH, Hennigsdorf, Germany; rehfeld@sphingotec-tx.de. 2. Sphingotec Therapeutics GmbH, Hennigsdorf, Germany. 3. Institute of Biochemistry, Graz University of Technology, Graz, Austria. 4. Department of Clinical Sciences, Clinical Research Center, Lund University, Malmö, Sweden.
Abstract
BACKGROUND: The ubiquitously expressed dipeptidyl peptidase 3 (DPP3) is involved in protein metabolism, blood pressure regulation, and pain modulation. These diverse functions of DPP3 are attributed to the degradation of bioactive peptides like angiotensin II. However, because of limitations in currently available assays for determination of active DPP3 in plasma, the exact physiological function of DPP3 and its role in the catabolism of bioactive peptides is understudied. Here, we developed 2 assays to specifically detect and quantify DPP3 protein and activity in plasma and validated DPP3 quantification in samples from critically ill patients. METHODS: Assay performance was evaluated in a sandwich-type luminometric immunoassay (LIA) and an enzyme capture activity assay (ECA). DPP3 plasma concentrations and activities were detected in a healthy, population-based cohort and in critically ill patients suffering from severe sepsis and septic shock. RESULTS: The DPP3-LIA and DPP3-ECA show an almost ideal correlation and very similar and robust performance characteristics. DPP3 activity is detectable in plasma of predominantly healthy subjects with a mean (±SD) of 58.6 (±20.5) U/L. Septic patients show significantly increased DPP3 plasma activity at hospital admission. DPP3 activities further increase in patients with more severe conditions and high mortality risk. CONCLUSION: We developed 2 highly specific assays for the detection of DPP3 in plasma. These assays allow the use of DPP3 as a biomarker for the severity of acute clinical conditions and will be of great value for future investigations of DPP3's role in bioactive peptide degradation in general and the angiotensin II pathway in specific.
BACKGROUND: The ubiquitously expressed dipeptidyl peptidase 3 (DPP3) is involved in protein metabolism, blood pressure regulation, and pain modulation. These diverse functions of DPP3 are attributed to the degradation of bioactive peptides like angiotensin II. However, because of limitations in currently available assays for determination of active DPP3 in plasma, the exact physiological function of DPP3 and its role in the catabolism of bioactive peptides is understudied. Here, we developed 2 assays to specifically detect and quantify DPP3 protein and activity in plasma and validated DPP3 quantification in samples from critically illpatients. METHODS: Assay performance was evaluated in a sandwich-type luminometric immunoassay (LIA) and an enzyme capture activity assay (ECA). DPP3 plasma concentrations and activities were detected in a healthy, population-based cohort and in critically illpatients suffering from severe sepsis and septic shock. RESULTS: The DPP3-LIA and DPP3-ECA show an almost ideal correlation and very similar and robust performance characteristics. DPP3 activity is detectable in plasma of predominantly healthy subjects with a mean (±SD) of 58.6 (±20.5) U/L. Septic patients show significantly increased DPP3 plasma activity at hospital admission. DPP3 activities further increase in patients with more severe conditions and high mortality risk. CONCLUSION: We developed 2 highly specific assays for the detection of DPP3 in plasma. These assays allow the use of DPP3 as a biomarker for the severity of acute clinical conditions and will be of great value for future investigations of DPP3's role in bioactive peptide degradation in general and the angiotensin II pathway in specific.
Authors: Alice Blet; Benjamin Deniau; Karine Santos; Dirk P T van Lier; Feriel Azibani; Xavier Wittebole; Benjamin G Chousterman; Etienne Gayat; Oliver Hartmann; Joachim Struck; Andreas Bergmann; Massimo Antonelli; Albertus Beishuizen; Jean-Michel Constantin; Charles Damoisel; Nicolas Deye; Salvatore Di Somma; Thierry Dugernier; Bruno François; Stephane Gaudry; Vincent Huberlant; Jean-Baptiste Lascarrou; Gernot Marx; Emmanuelle Mercier; Haikel Oueslati; Peter Pickkers; Romain Sonneville; Matthieu Legrand; Pierre-François Laterre; Alexandre Mebazaa Journal: Crit Care Date: 2021-02-15 Impact factor: 9.097
Authors: Shalinee Jha; Ulrike Taschler; Oliver Domenig; Marko Poglitsch; Benjamin Bourgeois; Marion Pollheimer; Lisa M Pusch; Grazia Malovan; Saša Frank; Tobias Madl; Karl Gruber; Robert Zimmermann; Peter Macheroux Journal: J Biol Chem Date: 2020-06-16 Impact factor: 5.157
Authors: Eva M Boorsma; Jozine M Ter Maaten; Kevin Damman; Dirk J van Veldhuisen; Kenneth Dickstein; Stefan D Anker; Gerasimos Filippatos; Chim C Lang; Marco Metra; Karine Santos; Adriaan A Voors Journal: Eur J Heart Fail Date: 2021-03-30 Impact factor: 15.534